Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04730999
- Collaborators
- Roche Pharma, Italy
- YGHEA, CRO Division of Ecol Studio spa
- Dr. Luca Boni U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino - IST NORD CBA
- Investigators
- Principal Investigator: Andrea Ardizzoni, Dr S. Orsola-Malpighi University Hospital - Dept. Oncology-Haematology Study Chair: Karim Rihawi, Dr S. Orsola-Malpighi University Hospital - Dept. Oncology-Haematology